Episode Details

This is the audio from RQM+ Live! #45, originally recorded 16 December, 2021.
 

Generating evidence of biocompatibility continues to be a significant challenge to regulatory submission success and product-to-market timelines.  And global requirements and interpretations continue to evolve, further increasing the challenge.  In this show, we will discuss the changes to standards in recent years, what’s on the horizon for 2022, and answers to common questions we receive like the following:

  • Is the biocompatibility approach different for US and EU? 
  • When should you consider a chemical characterization approach?
  • How do you use exemptions for intact skin devices made of common materials (US)?
  • What’s the best process for managing changes to material or manufacturing processes?
  • What can you change and still claim equivalence?
  • What new developments have there been in 2021?

Please join our esteemed panel of subject matter experts including former FDA CDRH and BSI leaders:

  • Jaishankar (Jai) Kutty, Ph.D. VP, Intelligence & Innovation
  • Nancy Morrison, RAC - Executive Director, Regulatory & Quality Consulting Services
  • Jonathan Gimbel, PhD - Executive Director, Technical Leadership, Clinical & Post-Market Practice
  • Kevin Go - Project Engineer (former FDA CDRH Lead Reviewer)

We are passionate about your success. Tell us more about your regulatory and quality needs so we can help.

Book a Consultation

GLOBAL BOTTOM CTA INSTRUCTIONS:

To display custom copy instead of global copy in this section, please go to Show Global Content for Bottom CTA? toggle in the "Contents" tab to the left, toggle it off, save, and then REFRESH the page editor, the custom text will then show up and ready to be edited.

Turning the global content back on will be the same process, go to the toggle and toggle it back on, save and refresh!